Turin, July 2021 – Corion Biotech signed an agreement with the University of Turin GMP cell factory which will support the Company in the GMP production of CB-ChMF-11, an innovative biological product for the treatment of Preeclampsia.

This is a pivotal milestone for the manufacturing development of our product.

The Officina Farmaceutica is located at the Molecular Biotechnology Center in Turin. It obtained the AIFA (Agenzia Italiana del Farmaco) authorization in July 2017 and it is recognized as a national and international center of excellence for the production of adult stem cells and clinical application for the treatment of rare diseases thanks to innovative technologies.